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Psychologic Modulation of the
Human Immune Response to
Varicella Zoster
G. Richard Smith, Jr, MD; James M. McKenzie;
Daniel J. Marmer, MS, MT; Russell W. Steele, MD
\s=b\Psychoimmunology, the interrelationship between the
brain/mind/psyche and the immune system, is now an estab-
lished area of scientific research. Based on prior investiga-
tions we hypothesized that an experienced meditator could
affect her delayed hypersensitivity reaction by a psychological
process. A single-case study design was employed in which
the subject was skin tested weekly with varicella zoster skin
test reagent. After baseline immunologic studies, she was
able, as hypothesized, to significantly reduce both the indura-
tion of her delayed hypersensitivity skin test reaction and in
vitro lymphocyte stimulation to varicella zoster. Then, as
predicted, she was able to allow her reaction to return to
baseline. As a confirmation of what is to our knowledge this
previously undescribed phenomenon, she was able to re-
produce the entire sequence nine months later. It appears that
this subject can intentionally modulate her immune response
by a psychologic mechanism.(Arch Intern Med 1985;145:2110-2112)
T^or centuries physicians have theorized about the possi-
*- ble role of the mind and/or psyche as a mediator between
health and disease. There have been countless postulated
mechanisms for this modulation. In recent years, attention
has turned to the immune system as one possible system
whereby the mind may affect, either negatively or
positively, the transition from health to disease and at times
back to health. This report will present data demonstrating
an apparent voluntary, direct, psychologically mediated
effect on the human immune system. Specifically, in a
carefully designed single-case protocol, a woman meditator
intentionally suppressed her cell-mediated immune re¬
sponse to varicella zoster viral antigen as measured in vivo
by delayed hypersensitivity skin test reactions and in vitro
by lymphocyte stimulation.
Direct evidence has been accumulating for several dec¬
ades linking the mind and the immune system.1 There is a
growing body of evidence demonstrating a direct link
between psychological or behavioral processes and the
immune system. Both animal and human data now provide
sound evidence that a psychic event may alter some aspects
of immune function.
In a series of studies attempting to modulate the immune
system, Black and associates2 successfuly modified a
clinical measure of cell-mediated immunity. Using four
highly selected tuberculin-positive male subjects, they
demonstrated an inhibition of delayed hypersensitivity
reaction to tuberculin (Mantoux reaction) via hypnosis.
After an extensive training period they forcefully sug-
gested to the hypnotized subjects that they not react to
further injections of tuberculin. Whenretested, all subjects
inhibited the Mantoux reaction.
In 1983 Smith and McDaniel3 reported another direct
psychologically mediated effect on the tuberculin reaction
in seven tuberculin-positive subjects. The subjects were
exposed to a behavioral conditioning paradigm in which
they expected the reaction on one arm to be positive and on
the other arm to be negative. When unbeknown to them the
tuberculin, or unconditioned stimulus, was switched to the
opposite arm, they had a significantly reduced response to
tuberculin. Their clinical reaction, measured by induration,
was reduced from a mean of 15 mm to a mean of 4 mm when
they expected their reaction to be negative.
In light of the above findings, we hypothesized that a
highly selected subject could use meditation or self-hypno¬
sis to modulate her immune response. The paradigm was a
simple, single-case design in which the subject was her own
control. She was given a skin test weekly for nine weeks.
During the first three weeks (phase 1) she was told to react
normally. The second three weeks (phase 2) she was asked
to try to inhibit her reaction using any psychologic practice
or technique she chose. Finally, for the final three weeks(phase 3) she was again asked to react normally. We
hypothesized that the immune response during the second
phase would be decreased compared with the first and third
phases.
METHODS
The subject, an experienced meditator, was known to have a
positive reaction to the varicella zoster (VZ) viral antigen. After
obtaining informed consent, we applied 0.1 mL of antigen to the
volar aspect of the right forearm. For three weeks of phase 1, she
was instructed to respond in a normal or unmodulated fashion. Her
skin tests were read at 24 and 48 hours. The skin tests were read
independently by two readers, one of whom was "blind" to the
protocol condition. After the 48-hour reading, blood was obtained
for in vitro assay of lymphocyte stimulation by VZ antigen. The
phase 2, three-week period served as the intervention period in
which the subject was asked to use whatever mechanism she
thought would be helpful to modulate or reduce her skin test
response. She was asked not to take medicines during this time,
specifically no steroids, and was asked to inform us if she became ill
in any way. Her skin tests were read and blood samples were
obtained on a weekly basis just as during the baseline study. Phase
3 served as a return to baseline, in which she was instructed to
allow her skin test to react in an unmodulated fashion for each of
three weeks.
Nine months after the first study period, the subject was studied
again with the same protocol. All skin tests used the Mantoux
technique with tuberculin syringes and 25-gauge needles. Tests
were read using the ballpoint pen technique described by Sokal.4
All readings were in millimeters.
Varicella zoster virus antigen was prepared from the Scott strain
ofVZ and human diploid cells as reported by Steele and associates.5
The skin test antigen completed the necessary protocols for an
investigative new drug and has been assigned number BB-IND
1563.
Antigen-induced lymphocyte stimulation was performed on lym¬
phocytes separated from peripheral whole blood obtained after the
48-hour readings. Lymphocytes were separated from whole blood
by centrifugation on a Ficoll-Hypaque gradient. Using a micro-
pipette, 0.1 mL of the lymphocyte suspension (2 x 105 lymphocytes)
was added to an equal volume of various concentrations of VZ
antigen each in triplicate, in a sterile microtiter plate. The cultures
were incubated for five days using a 24-hour tritiated thymidine
pulse. A harvesting apparatus, as previously described, was
employed for separation of the stimulated lymphocytes on glass
fiber filters for washing of these cells and for recovery of tritiated
thymidine uptake.6 Variation among triplicate samples with this
antigen have averaged 26%. Data were analyzed by absolute counts
per minute (cpm) in cultures that contained VZ antigen and by
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Fig 1.—Induration at 48 hours. Solid line is first study period; broken
line, second study period; and heavy line, mean.
calculation of a blastogenic index: cpm of tritiated thymidine
uptake for lymphocytes incubated with VZ divided by cpm after
incubation with medium alone. These determinations were made
for each of three concentrations of VZ antigen.
The subject is a 39-year-old woman who has followed an Eastern
religious practice for the last nine years. During most of this time,
as part of her religious practice, she would usually meditate once or
twice daily for about 30 minutes. For the last three years, she has
followed a specific tantric generation meditation practice whereby
"higher energies" are visualized and she seeks to transform herself
into those energies.
During the phase 2 periods of the original and repeat experi¬
ment, she would usually reserve about five minutes of her daily
meditation for attention to the study. First she would dedicate her
intention concerning the study for universal good instead of self-
advancement. She would also tell her body not to violate its wisdom
concerning her defense against infection. Finally she would vi¬
sualize the area of erythema and induration getting smaller and
smaller. Soon after each phase 2 injection, she would pass her hand
over her arm, sending "healing energy" to the injection site.
RESULTS
The subject remained healthy throughout both study
periods. There was high interrater reliability between the
two skin-test readers (Pearson's correlation coefficient =
.86). Figure 1 represents the induration measured at 48
hours for each phase. The solid line represents the first
study period, the broken line is the second study period,
and the heavy line is the mean.
For lymphocyte stimulation assays, control cultures (me¬
dium alone) averaged 2,641 ± 798 cpm and had no significant
influence on calculation of the blastogenic index. Changes
for the optimal concentration of antigen in all cases were
representative of changes seen with other VZ antigen
concentrations in the dose-response curve. Therefore, for
simplicity, data are presented using the mean blastogenic
index with optimal VZ antigen concentrations for the study
periods. Figure 2 represents the mean blastogenic index.
The likelihood of changes in induration or blastogenic index
happening as predicted by chance alone is P<.001 (binomial
expansion).
COMMENT
The data confirmed the hypothesis, that this subject
could voluntarily modulate her immune responses by apsychic mechanism. Both a clinical measure, delayed hyper¬
sensitivity, and an in vitro measure, lymphocyte stimula¬
tion of immune response, were affected. In other words, it
appears that the subject, acting with intention, was able to
affect not only her skin test response but also the response
of her lymphocytes studied in the laboratory.
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Fig 2.—Mean blastogenic index for two study periods.
These data are entirely consistent with the growing body
of evidence that uncontrollable psychological events are
associated with immune changes.79 Ader and Cohen10 have
provided important data linking psychic events, in this case
learning or behavioral conditioning, with modulation of the
immune response in animals. Their carefully controlled and
designed studies have demonstrated decreased antibody
production, decreased graft-vs-host response, and pro¬
longed survival in an immunologically mediated disease.10"12
They used a Pavlovian (learning) paradigm in which they
paired saccharin, the conditioned stimulus, with cy-
clophosphamide, the unconditioned stimulus, and obtained
reproducible immunosuppression when the conditioned an¬
imals were reexposed to saccharin alone. In effect, animals
"learned" that when they were given saccharin they sup¬
pressed their immune response. Their work has been
reproduced in two independent laboratories.1314
Studies of human subjects have been less rigorously
controlled, yet several intriguing reports have been pub¬
lished linking unavoidable life events with suppressed im¬
mune response.15"17
To our knowledge these are the first published data of an
intentional direct psychological modulation of the human
immune system. The results from this study certainly
cannot be generalized to all humans; however, perhaps
other people have the ability to modulate their immune
response or to develop the capacity to do so. Certainly,
these data, along with the previously cited results, should
allow for many new carefully designed studies to be under¬
taken.
If it proves to be the case that humans can significantly
modulate their immune response, then two important out¬
comes may occur. The mechanism of infectious or neoplastic
disease onset associated with various psychologic processes
such as hopelessness or depression can possibly be better
understood. Perhaps, also, intentional modulation can be
used therapeutically to increase or decrease immune re¬
sponse, depending on the particular disease state.
This investigation was supported by research grants from the University
of Arkansas for Medical Sciences Foundation Fund for Medical Research and
the Marie Wilson Howells Fund.
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Sarcoidosis and Reactive
Pulmonary Hypertension
Robyn J. Barst, MD, Scott J. Ratner, MD
\s=b\Despite diffuse disease of the lungs (often with wide-
spread inflammation or obliteration of blood vessels) in sar-
coidosis, pulmonary hypertension is uncommon, occurring in
1% to 4% of cases. We report a case of sarcoidosis and severe
pulmonary hypertension that, in striking contrast to other
reports, occurred in the absence of obliterative pulmonary
vascular disease. We therefore examined the possibility of
whether an abnormality in pulmonary vascular tone might be a
cause of the pulmonary hypertension. In pharmacologic stud-
ies, we demonstrated pulmonary vasodilatation and, in re-
sponse to increased pulmonary blood flow, the elaboration of
the pulmonary vasoconstricting eicosanoid, thromboxane.
(Arch Intern Med 1985;145:2112-2114)
Oarcoidosis is a multisystem disease characterized patho-
^ logically by the presence of noncaseating granulomas in
affected tissues. At least 90% of patients have pulmonary
manifestations due to alveolitis, noncaseating granulomas,
and varying degrees of fibrosis or parenchymal alteration.1
Despite the frequent occurrence of significant parenchymal
destruction, pulmonary hypertension is uncommon, occur¬
ring in 1% to 4% of cases.1 It has been suggested that the
pulmonary hypertension results from severe fibrosis and
destruction of the pulmonary vascular bed.1
We report a case of sarcoidosis and severe pulmonary
hypertension that, in striking contrast to other reports,
occurred in the absence of obliterative pulmonary vascular
disease. Because obliterative vascular disease was not seen,
we examined the possibility of whether an abnormality inpulmonary vascular tone caused the pulmonary hyperten¬
sion. In pharmacologie studies of the pulmonary vascular
bed, we demonstrated pulmonary vasoreactivity (the bed
could be dilated) and, in response to increased pulmonary
blood flow, the elaboration of a pulmonary vasoconstricting
eicosanoid.
REPORT OF A CASE
A 23-year-old woman was admitted to the hospital for evaluation
of exertional chest pain and syncope of one month's duration. Her
health and family history were unremarkable and she took no
regular medication. On examination she had a right ventricular
heave and a loud pulmonary component of the second heart sound.
A chest roentgenogram revealed clear lung fields with a prominent
pulmonary artery silhouette. The electrocardiogram and echocar-
diogram were consistent with right ventricular enlargement and
pulmonary hypertension. On cardiac catheterization the pulmo¬
nary arterial pressure was 108/52 mm Hg (normal, 15 to 30/3 to
12 mm Hg) and there was no evidence of an intracardiac shunt.
Cardiac index was 1.9 L/min/sq m (normal, 2.5 to 4.2 L/min/sq m).
The hemoglobin level was 15.5 g/dL. The alkaline phosphatase level
was 452 units/L (normal, <100 units/L) and -y-glutamyl transpep-
tidase was 316 units/L (normal, <35 units/L).
Repeated chest roentgenograms revealed hilar adenopathy and
parenchymal infiltrates. A liver biopsy specimen showed multiple
noncaseating granulomas. A Kveim test was interpreted as
positive based on the criteria established by Steigledger and co-
workers2; the patient was tested with the antigen prepared accord¬
ing to Nelson.3 Arterial oxygen tension was 78 mm Hg, arterial
carbon dioxide tension was 32 mm Hg, and pH was 7.42 breathing
room air. An open lung biopsy was performed (Figure). The
parenchyma was studded with small to medium-sized noncaseating
granulomas that did not involve blood vessels. Medial hypertrophy,
slight mural fibrosis, and fibromuscular proliferation were present
in the pulmonary arteries. Pulmonary hypertensive lesions were
focal and grade 1 to 3 on the Heath-Edwards scale. There was no
evidence of fibrosis, vasculitis, thrombosis, or embolism. Micro¬
organisms were not detected.
The stable breakdown products of prostacyclin (6-ket0-PGFlo)
and thromboxane A2 (TXB2) were measured by radioimmunoassay
using commercially available kits. The patient's peripheral venous
plasma TXB2 was 60 pg/mL (laboratory normal, <80 pg/mL) and 6-
keto-PGFla was 130 pg/mL (laboratory normal, =s80 pg/mL). A
detailed study of pulmonary vasoreactivity and vasoactive medi¬
ators was performed during repeated cardiac catheterization.
Administration of epoprostenol (prostacyclin), nitroglycerin, and
nifedipine demonstrated that vasodilatation of the pulmonary
vascular bed could be induced (Table). An increase in the concen¬
tration of TXB2 was detected from the pulmonary artery to the
aorta, concomitant with the increase in flow seen with administra¬
tion of epoprostenol, nitroglycerin, and nifedipine, suggestive of
pulmonary production of thromboxane A2 (TXA2). No trans-
pulmonary gradient of 6-keto-PGFla was detected during adminis¬
tration of nitroglycerin or nifedipine.
Despite treatment with prednisone (1 mg/kg/day) for two
months, the patient developed progressive right ventricular fail¬
ure. In an attempt to reverse her rapidly deteriorating condition,
nifedipine and cyclophosphamide were added; she died two weeks
later.
COMMENT
Pulmonary hypertension is an unusual but well-recog¬
nized complication of sarcoidosis. Rizzato and co-workers4
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